Fresh off its approval in the fourth quarter of 2023 for the treatment of obese and overweight adults, Eli Lilly and Company’s Zepbound (tirzepatide) looks likely to win approval in a related disease area, moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, thanks to positive topline Phase III results.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?